Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Tables)

v3.20.2
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Tables)
6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Schedule of Noncontrolling Interest

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows:

 

    Six Months
Ended
June 30, 2020
    Year Ended
December 31, 2019
 
NCI - equity (deficit) - beginning of period   $ (814 )   $ (162 )
Minority Interest investment in Solys Diagnostics Inc           889  
Minority Interest share subscription receivable - Solys Diagnostics Inc.           (889 )
Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise     5        
Net loss attributable to NCI - Lucid Diagnostics Inc.     (640 )     (801 )
Net loss attributable to NCI - Solys Diagnostics Inc.     (62 )     (10 )
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan     26       159  
NCI - equity (deficit) - end of period   $ (1,485 )   $ (814 )